Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520540 | 1.00 | SIRT6 (0.64) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL519355 | 0.88 | SIRT6 (0.72) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL2206521 | 0.83 | SIRT6 (0.67) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL3712921 | 0.83 | ALDH1A1 (0.55) | SIRT6ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL519153 | 0.82 | SIRT6 (0.67) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL519584 | 0.82 | PRKDC (0.41) | SIRT6MAPTMAPK1HTT | |
| SCHEMBL519585 | 0.82 | PRKDC (0.41) | SIRT6MAPTMAPK1HTT | |
| SCHEMBL519583 | 0.82 | PRKDC (0.41) | SIRT6MAPTMAPK1HTT | |
| SCHEMBL520304 | 0.82 | LMNA (0.60) | SIRT6ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL309810 | 0.80 | ALDH1A1 (0.70) | SIRT6ALDH1A1LMNAMAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SIRT6 3364/4885ALDH1A1 779/4885LMNA 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.